RNA · Atrium Therapeutics, Inc.
$8.20
+0.49% last session
End-of-day data · close of 2026-10-23
Market cap
<$1M
Enterprise value
<$1M
Trailing P/E
—
Forward P/E
-1.4
Dividend yield
0.0%
Beta
—
Avg volume
0M
Employees
—
Daily Change %
0.49%
5 Days Change
6.39%
10 Days Change
5.29%
30 Days Change
-2.04%
60 Days Change
-40.09%
Month to Day Change
0.25%
Year to Day Change
—
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — RNA
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-22
Latest call per bank · past 12 months
Wells Fargo
Overweight$25.00
+204.9% vs priceRBC Capital
Sector Perform$72.00
+778.0% vs priceCitigroup
Neutral$72.00
+778.0% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-22 | Roth Capital | Initiates | Buy | $0.00 → $15.00 |
| 2026-08-14 | HC Wainwright & Co. | Reiterates | Buy | $25.00 |
| 2026-08-06 | HC Wainwright & Co. | Initiates | Buy | $0.00 → $25.00 |
| 2026-06-18 | Cantor Fitzgerald | Initiates | Overweight | $0.00 → $25.00 |
| 2026-05-15 | Leerink Partners | Initiates | Outperform | $0.00 → $25.00 |
| 2026-03-11 | Wells Fargo | Initiates | Overweight | $0.00 → $25.00 |
| 2025-11-11 | Chardan Capital | Maintains | Neutral | $72.00 |
| 2025-10-29 | TD Cowen | Downgrade | Buy → Hold | $78.00 → $74.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- neutral: RSI (14): RSI is 42 — neutral momentum, neither overbought nor oversold.
- bearish: Price vs 50-day MA: Trading 20.1% below the 50-day MA ($10.26).
- bullish: MACD (12,26,9): MACD histogram is positive (+0.18) — short-term momentum is improving.
- bearish: 52-week range: Price is within 10% of the 52-week low ($7.61).
RNA Price Chart
Loading chart for RNA…
Fundamentals
About Atrium Therapeutics, Inc.
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. It has a research collaboration and license agreement with Bristol-Myers Squibb Company and Eli Lilly and Company. The company was incorporated in 2025 and is headquartered in San Diego, California.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$133B 18.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 6.5% YTD
MRNA
Moderna, Inc.
$80B 587.1% YTD
ARGX
argenx SE
$55B 4.1% YTD
ONC
BeOne Medicines Ltd.
$43B 25.8% YTD
RVMD
Revolution Medicines, Inc.
$40B 135.6% YTD
RPRX
Royalty Pharma plc
$37B 67.3% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.